Actively Recruiting
Evaluating Modafinil for Severe Fatigue in Adults with Inactive Inflammatory Bowel Disease A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Led by Radboud University Medical Center · Updated on 2026-09-14
60
Participants Needed
2
Research Sites
17 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether modafinil can reduce severe fatigue in adults aged 18 to 75 years who have quiescent inflammatory bowel disease IBD, which includes Crohns disease and ulcerative colitis. Fatigue is a common and burdensome symptom in IBD even when the disease is inactive, affecting quality of life, daily functioning, and work productivity. This trial aims to compare modafinil with placebo to see if it improves fatigue and to assess its safety and tolerability in this patient group. Participants receive either modafinil or a matching placebo for 8 weeks. The medication starts at 100 mg daily and may be increased up to 300 mg daily based on individual response and side effects. Study visits include one initial screening with assessments such as blood tests, stool testing, ECG, and disease activity evaluation. After baseline, most visits and assessments are conducted remotely to reduce participant burden. Participants complete questionnaires on fatigue, quality of life, sleep, mood, and work productivity at baseline and weeks 4, 8, and 12. They also perform an online effort-based decision-making task at baseline and week 8. Throughout the treatment period, participants are regularly contacted to monitor effects and any side effects, with dose adjustments as needed. The main measure is the mean difference in fatigue scores at week 8. Secondary measures include changes in various questionnaires related to fatigue, quality of life, sleep, mood, anxiety, and work productivity, as well as safety assessments up to 30 days after treatment ends. Blood biomarkers will also be explored to understand biological factors linked to fatigue and treatment response. The total study duration for participants includes treatment and a 4-week follow-up period.
CONDITIONS
Brief Title
Modafinil for Debilitating Fatigue in Quiescent Inflammatory Bowel Disease MODIFI-IBD Trial)
Research Team
M
Manal Aourag, MD
J
Joris Hendriks, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here